Executive Moves | Healthcare | BioTuesdays by Kilmer Lucas IR

Executive Moves

Ondine Biomedical names Simon Sinclair as CMO

Ondine Biomedical (LON:OBI) appointed Simon Sinclair, M.D., Ph.D., as chief medical officer, as the company prepares to start a U.S. Phase 3 trial of its nasal photodisinfection technology. Dr. Sinclair has more than 20...

June 1, 2023

Executive Moves

Theralase names Roger DuMoulin-White as president and CEO

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Roger DuMoulin-White as president and CEO, succeeding Arkady Mandel, M.D., Ph.D., as interim CEO. Dr. Mandel will continue as CSO and a director. Mr. DuMoulin...

May 25, 2023

Executive Moves

Conavi Medical names CV device veteran Brian Chambless as CCO

Conavi Medical appointed accomplished cardiovascular medical device industry veteran, Brian Chambless, to the newly created position of chief commercial officer (CCO). In an executive management career spanning more...

May 15, 2023

Executive Moves

PharmaJet names Nathalie Landry as CSO

PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...

May 2, 2023

Executive Moves

Jeffrey Dayno named president, CEO of Harmony Biosciences

Harmony Biosciences (NASDAQ:HRMY) appointed Jeffrey Dayno, M.D., as president and CEO, and a member of the board. Dr. Dayno, a nationally recognized neuroscience expert, joined Harmony as CMO and EVP when the company...

April 24, 2023

Executive Moves

IntelGenx makes organizational changes to support global growth strategy

IntelGenx Technologies (TSX:IGX; OTCQB:IGXT) appointed Dwight Gorham as CEO, effective immediately, succeeding the company’s founder, Horst Zerbe, Ph.D., who has retired as CEO, but will continue as chairman. The CEO...

April 13, 2023

Executive Moves

NervGen appoints Michael Kelly as president, CEO

NervGen Pharma (TSXV:NGEN; OTCQX:NGENF) named Michael Kelly to the position of president and CEO, effective April 10, as well as a member of the board. In a statement, Bill Radvak, executive chairman of NervGen, said Mr...

April 10, 2023

Executive Moves

Hepion expands SAB with appointments of four liver disease KOLs

Hepion Pharmaceuticals (NASDAQ:HEPA) added four new internationally recognized thought leaders to its scientific advisory board (SAB), effective immediately. These new members, who bring decades of liver disease...

March 30, 2023

Executive Moves

OpSens names John Hannigan as CFO

OpSens (TSX:OPS; OTCQX:OPSSF) appointed John Hannigan as CFO, effective immediately. Mr. Hannigan is a highly experienced financial executive with more than 22 years of proven financial expertise with domestic and...

March 27, 2023

Executive Moves

Dylan Dupuis joins ROTH MKM healthcare research team

Dylan Dupuis, Ph.D., has joined ROTH MKM’s healthcare research team as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...

March 13, 2023

Executive Moves

Heron names renowned healthcare investor Kevin Kotler to the board

Heron Therapeutics (NASDAQ:HRTX) appointed three new directors to the board, including Kevin Kotler, a renowned healthcare investor, founder and portfolio manager of Broadfin Capital. Mr. Kotler has over 30 years of...

February 24, 2023

Executive Moves

Elucid names Scott Burger as CCO

Elucid, a closely-held medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, appointed Scott Burger as chief commercial officer. His...

January 26, 2023

Executive Moves

Raymond James adds 3 senior bankers to healthcare practice

Raymond James Ltd. (CNW Group/Raymond James Ltd.) Raymond James again expanded its healthcare investment banking practice with the addition of three senior bankers. Joining the firm as managing directors are Jeff...

January 12, 2023

Executive Moves

Soricimed appoints leading cancer researcher Dr. Siqing Fu to SAB

Soricimed Biopharma appointed Dr. Siqing Fu, a North American leader in cancer research, to its scientific advisory board. Dr. Fu has more than 20 years of experience in cancer research and is currently a professor in...

December 14, 2022

Executive Moves

Ripple Therapeutics elevates director Dr. Jonathan Talamo to chairman

Closely-held Ripple Therapeutics appointed Jonathan Talamo, M.D., currently a member of the board, to be chairman. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology, with...

November 29, 2022

Executive Moves

JD Finley named interim CEO of Palisade Bio

Palisade Bio (NASDAQ:PALI) named JD Finley, CFO, as interim CEO, replacing Thomas Hallam, Ph.D., effective Oct. 10. In a statement, James Neal, chairman of Palisade, said Dr. Hallam was “instrumental in the development...

October 11, 2022

Executive Moves

Kumaraguru Raja joins ROTH healthcare research team

Kumaraguru Raja, Ph.D., joined ROTH Capital Partners healthcare research team, as managing director, senior research analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap...

October 11, 2022

Executive Moves

Sigyn Therapeutics strengthens board with 3 appointments

Sigyn Therapeutics (OTCQB:SIGY) appointed Richa Nand, Jim Dorst, and Christopher Wetzel to its board, effective Oct. 10, 2022. “As we transition toward the next phase of our clinical endeavors, it is an opportune...

October 4, 2022

Executive Moves

Paul Brennan steps down as CEO of NervGen

Paul Brennan Paul Brennan is stepping down as president, CEO and a director of NervGen Pharma (OTCQX:NGENF; TSXV:NGEN), effective immediately. The board appointed current executive chairman, Bill Radvak, as interim CEO...

September 23, 2022

Executive Moves

Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion

Verséa Holdings appointed Rob Sambursky, M.D., as president to support its corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business...

August 16, 2022

Executive Moves

Titan Pharma names new CEO, expands board

Titan Pharmaceuticals (NASDAQ:TTNP) appointed Activist Investing’s David Lazar as interim chairman and CEO, with a mandate to lead Titan’s continuing review of strategic alternatives. He succeeds Marc Rubin, M.D...

August 16, 2022

Executive Moves

Enzo Biochem appoints Matthew Kupferberg as general counsel

Enzo Biochem (NYSE:ENZ) named Matthew Kupferberg as the company’s in-house general counsel. He was most recently general counsel, chief compliance officer and privacy officer of Digital Medical Technologies, a...

August 3, 2022

Ondine Biomedical names Simon Sinclair as CMO

Theralase names Roger DuMoulin-White as president and CEO

Conavi Medical names CV device veteran Brian Chambless as CCO

PharmaJet names Nathalie Landry as CSO

Jeffrey Dayno named president, CEO of Harmony Biosciences

IntelGenx makes organizational changes to support global growth strategy

NervGen appoints Michael Kelly as president, CEO

Hepion expands SAB with appointments of four liver disease KOLs

OpSens names John Hannigan as CFO

Dylan Dupuis joins ROTH MKM healthcare research team

Heron names renowned healthcare investor Kevin Kotler to the board

Elucid names Scott Burger as CCO

Raymond James adds 3 senior bankers to healthcare practice

Soricimed appoints leading cancer researcher Dr. Siqing Fu to SAB

Ripple Therapeutics elevates director Dr. Jonathan Talamo to chairman

JD Finley named interim CEO of Palisade Bio

Kumaraguru Raja joins ROTH healthcare research team

Sigyn Therapeutics strengthens board with 3 appointments

Paul Brennan steps down as CEO of NervGen

Verséa Holdings names Rob Sambursky as president to lead ophthalmic expansion

Titan Pharma names new CEO, expands board

Enzo Biochem appoints Matthew Kupferberg as general counsel

General

More